Green Cross Lab Cell Corporation (144510) - Total Liabilities

Latest as of September 2025: ₩134.23 Billion KRW ≈ $90.97 Million USD

Based on the latest financial reports, Green Cross Lab Cell Corporation (144510) has total liabilities worth ₩134.23 Billion KRW (≈ $90.97 Million USD) as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.

Green Cross Lab Cell Corporation - Total Liabilities Trend (2015–2024)

This chart illustrates how Green Cross Lab Cell Corporation's total liabilities have evolved over time, based on quarterly financial data. See working capital position of Green Cross Lab Cell Corporation to evaluate short-term liquidity relative to the company's equity base.

Green Cross Lab Cell Corporation Competitors by Total Liabilities

The table below lists competitors of Green Cross Lab Cell Corporation ranked by their total liabilities.

Company Country Total Liabilities
Lotte Chemical Titan Holding BHD
KLSE:5284
Malaysia RM12.88 Billion
Fks Multi Agro Tbk
JK:FISH
Indonesia Rp295.89 Million
Talisker Resources Ltd
TO:TSK
Canada CA$54.58 Million
Berjaya Assets Bhd
KLSE:3239
Malaysia RM1.19 Billion
ChargePoint Holdings Inc
NYSE:CHPT
USA $730.09 Million
Lanson BCC SA
PA:ALLAN
France €725.61 Million
Eaton Vance New York MBF
NYSE MKT:ENX
USA $86.56 Million
Nkarta Inc
NASDAQ:NKTX
USA $86.21 Million

Liability Composition Analysis (2015–2024)

This chart breaks down Green Cross Lab Cell Corporation's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see Green Cross Lab Cell Corporation market capitalisation.

Liquidity & Leverage Metrics

Key Metrics Explained

Metric Value Description
Current Ratio 0.60 Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio N/A More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio N/A Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity 0.31 Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets 0.24 Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how Green Cross Lab Cell Corporation's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for Green Cross Lab Cell Corporation (2015–2024)

The table below shows the annual total liabilities of Green Cross Lab Cell Corporation from 2015 to 2024.

Year Total Liabilities Change
2024-12-31 ₩120.56 Billion
≈ $81.70 Million
-2.53%
2023-12-31 ₩123.69 Billion
≈ $83.82 Million
-10.42%
2022-12-31 ₩138.07 Billion
≈ $93.57 Million
+2.60%
2021-12-31 ₩134.57 Billion
≈ $91.20 Million
+360.97%
2020-12-31 ₩29.19 Billion
≈ $19.78 Million
+21.56%
2019-12-31 ₩24.02 Billion
≈ $16.27 Million
+151.56%
2018-12-31 ₩9.55 Billion
≈ $6.47 Million
+35.76%
2017-12-31 ₩7.03 Billion
≈ $4.77 Million
+9.59%
2016-12-31 ₩6.42 Billion
≈ $4.35 Million
-18.81%
2015-12-31 ₩7.90 Billion
≈ $5.36 Million
--

About Green Cross Lab Cell Corporation

KQ:144510 Korea Diagnostics & Research
Market Cap
$179.74 Million
₩265.23 Billion KRW
Market Cap Rank
#17071 Global
#675 in Korea
Share Price
₩17650.00
Change (1 day)
-2.86%
52-Week Range
₩15710.00 - ₩27500.00
All Time High
₩126167.70
About

GC Cell Corporation develops cell therapy products. It also provides cell banking, sample inspection, clinical trial, and bio logistics services. Its main product is Immuncell-LC. GC Cell Corporation has strategic agreement with Lukas Biomedical Co., Ltd. to develop Cell therapy. The company was formerly known as Green Cross Lab Cell Corporation and changed its name to GC Cell Corporation in Nove… Read more